Escitalopram Oxalate Tablets

Escitalopram enhances the effects of 5-hydroxytryptamine (5-HT) in the central nervous system and inhibits the reuptake of 5-hydroxytryptamine. It is clinically used to treat depression. Animal studies have shown that escitalopram is a selective serotonin reuptake inhibitor (SSRI), but has a weak effect on the reuptake of norepinephrine and dopamine, which is 100 times that of the dextrorotatory enantiomer of citalopram. Escitalopram has no or very little effect on 5-hydroxytryptamine 1-7 receptors or other receptors including α and β adrenaline, dopamine 1-5, histamine 1, muscarinic 1-5 and benzodiazepine receptors. In addition, it has no effect on Na, K, Cl- and Ca ion channels.

1. Treatment of major depressive disorder (MDD): Major depressive disorder is characterized by significant or persistent depression or agitation (lasting at least 2 weeks), including the following symptoms: depression, loss of interest, significant changes in weight or appetite, insomnia or drowsiness, psychomotor excitement or retardation, excessive fatigue, guilt or inferiority, slow thinking or inattention, suicidal attempts or thoughts. 2. Generalized anxiety disorder (GAD): manifested as excessive anxiety and worry, lasting at least 6 months. The main symptoms are: irritability, fatigue, inattention, excitement, muscle tension and sleep disorders.

1 Major depression: The starting dose is 10 mg once a day, which can be increased to 20 mg once a day after one week, taken orally in the morning or evening. In general, treatment should be continued for several months or even longer. It is recommended that elderly patients or patients with liver dysfunction take 10 mg once a day, and patients with mild or moderate renal insufficiency do not need to adjust the dose. Use with caution in patients with severe renal insufficiency. 2 Generalized anxiety: The starting dose is 10 mg once a day, which can be increased to 20 mg once a day after one week, taken orally in the morning or evening. This drug can be switched to at least 14 days after monoamine oxidase inhibitors (MAOIs) are discontinued. Similarly, monoamine oxidase inhibitors can be used only 14 days after this drug is discontinued. The dose should be gradually reduced when the drug is discontinued.

About 5% of patients experience insomnia, impotence, nausea, constipation, sweating, dry mouth, fatigue, and drowsiness. About 2% of patients experience headaches, upper respiratory tract infections, back pain, pharyngitis, and anxiety. Occasionally, it has been reported to cause mania or hypomania or hyponatremia. Patients with a history of convulsions should use it with caution. There are no significant changes in laboratory parameters. There are no obvious abnormalities in the electrocardiogram.

seal.

5 mg